Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort.
Makito MiyakeNobutaka NishimuraYuki OdaTatsuki MiyamotoChihiro OhmoriNorimi TakamatsuYoshitaka ItamiAkira TachibanaYoshihiro MatsumotoKeisuke KibaAtsushi TomiokaHiroaki YamamotoEijiro OkajimaKuwata MasaomiKeichi SakamotoMitsuru TomizawaTakuto ShimizuKenta OhnishiShunta HoriYosuke MorizawaDaisuke GotohYasushi NakaiKazumasa TorimotoNobumichi TanakaKiyohide Fujimotonull nullPublished in: Japanese journal of clinical oncology (2023)
Here, we report real-world evidence for enfortumab vedotin therapy in Japan. Tumour responses and safety profiles were comparable with those of clinical trials on this novel treatment.